Study Finds Implanted Device Helps Patients With Central Sleep Apnea
More than 1,000 nurses have chosen Ohio State's Wexner Medical Center as
the place to pursue their careers. In the most recent publication of
"Best Doctors in America," 555 are affiliated with The Ohio State
University Wexner Medical Center.
New Drug Candidate Found for Fungal Lung Infections
Home to one of the largest and most comprehensive health sciences
campuses in America, The Ohio State University Wexner Medical
Center offers the opportunity to work with and learn from world-renowned
faculty.
COLUMBUS,
Ohio – On a molecular level, you have more in common with shower
curtain mold or the mushrooms on your pizza than you might think. Humans
and fungi share similar proteins, a biological bond that makes curing
fungal infections difficult and expensive. Current costs to treat these
stubborn infections can top $50,000 per patient, and no new classes of
antifungal drugs that treat systemic infections have been introduced for
at least 20 years.
Now, researchers at The Ohio State University Wexner Medical Center
have discovered a new compound that could be developed as an antifungal
drug to treat histoplasmosis and cryptococcosis, two types of fungal
infections that are naturally drug-resistant.
Generally,
people with weakened immune systems are more likely to develop
life-threatening fungal infections. However, the airborne fungus Histoplasma capsulatum, which causes histoplasmosis, can infect healthy people as well.
“Histoplasmosis
is an unusual fungal disease because anyone can be infected, not just
people with compromised immune systems. Like tuberculosis, Histoplasma
infects healthy hosts, attacks their lungs, and can lie dormant in
immune cells for years, later causing reactivation disease,†said Chad Rappleye, PhD, a microbiologist in the Center for Microbial Interface Biology
at Ohio State’s Wexner Medical Center and in the Department of
Microbial Infection and Immunity at Ohio State’s College of Medicine.
“So this is an unrecognized public health threat that’s needed better
treatment options for some time.†- See more at:
http://medicalcenter.osu.edu/mediaroom/releases/Pages/New-Drug-Candidate-for-Fungal-Lung-Infections.aspx#sthash.JC5fA1OH.dpuf
COLUMBUS,
Ohio – On a molecular level, you have more in common with shower
curtain mold or the mushrooms on your pizza than you might think. Humans
and fungi share similar proteins, a biological bond that makes curing
fungal infections difficult and expensive. Current costs to treat these
stubborn infections can top $50,000 per patient, and no new classes of
antifungal drugs that treat systemic infections have been introduced for
at least 20 years.
Now, researchers at The Ohio State University Wexner Medical Center
have discovered a new compound that could be developed as an antifungal
drug to treat histoplasmosis and cryptococcosis, two types of fungal
infections that are naturally drug-resistant.
Generally,
people with weakened immune systems are more likely to develop
life-threatening fungal infections. However, the airborne fungus Histoplasma capsulatum, which causes histoplasmosis, can infect healthy people as well.
“Histoplasmosis
is an unusual fungal disease because anyone can be infected, not just
people with compromised immune systems. Like tuberculosis, Histoplasma
infects healthy hosts, attacks their lungs, and can lie dormant in
immune cells for years, later causing reactivation disease,†said Chad Rappleye, PhD, a microbiologist in the Center for Microbial Interface Biology
at Ohio State’s Wexner Medical Center and in the Department of
Microbial Infection and Immunity at Ohio State’s College of Medicine.
“So this is an unrecognized public health threat that’s needed better
treatment options for some time.†- See more at:
http://medicalcenter.osu.edu/mediaroom/releases/Pages/New-Drug-Candidate-for-Fungal-Lung-Infections.aspx#sthash.JC5fA1OH.dpuf
